Clinical trial
Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who…
NCT00413270 · Novartis Pharmaceuticals, Industry · No longer available
Key facts
| NCT number | NCT00413270 |
|---|---|
| Title | Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant |
| Official title | A Canadian Open-label, Multicenter, Expanded Access Study of Oral Nilotinib in Adult Patients With Imatinib-resistant or -Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase, or Chronic Phase |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | No longer available |
| Study type | Expanded Access |
| Conditions | Chronic Myelogenous Leukemia |
| Intervention type | Drug |
| Interventions | nilotinib |
| Start date | Dec 1, 2006 |
| First posted | Dec 19, 2006 |
| Last update posted | Jul 13, 2011 |
| Countries | Canada |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: